Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Journal:

The Lancet

Published:

2025-08-16

DOI:

10.1016/s0140-6736(25)01073-6

Affiliations:

9

Authors:

18

Go to article

Institutions	Authors	Share
Akero Therapeutics, United States of America (USA)	11.000000 11.000000	0.61
Covenant Metabolic Specialists, United States of America (USA)	1.000000	0.06
Lucas Research, United States of America (USA)	1.000000	0.06
Velocity Clinical Research, United States of America (USA)	1.000000	0.06
Pacific Rim Pathology, United States of America (USA)	1.000000	0.06
Liverpat, France	1.000000	0.06
Summit Clinical Research, LLC, United States of America (USA)	1.000000	0.06
Houston Methodist Hospital, United States of America (USA)	0.500000	0.03
Houston Research Institute, United States of America (USA)	0.500000	0.03

Interested in Clinical Sciences?